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Abstract
Background: Staphylococcus aureus (SA) is a commensal bacterium representing one of the most important
components of the skin microbiome, mostly isolated in the anterior nares. A higher rate of SA nasal colonization in
patients affected by Wegener’s granulomatosis and rheumatoid arthritis compared with healthy subjects (HS) has
been described. No studies focusing on systemic lupus erythematosus (SLE) are available. We aimed at analyzing
the prevalence of SA nasal carriers in an SLE cohort and evaluating correlation between nasal colonization and
clinical, laboratory and therapeutic features.
Methods: We enrolled 84 patients with SLE (number of male/female patients 6/78; mean age 41.3 ± 12.2 years,
mean disease duration 142.1 ± 103.8 months) and 154 HS blood donors. Patients with SLE underwent a physical
examination and the clinical/laboratory data were collected. All the patients with SLE and the HS received a nasal
swab for SA isolation and identification.
Results: SA nasal colonization prevalence was 21.4 % in patients with SLE and 28.6 % in HS (P not significant). We
analyzed patients with SLE according to the presence (n = 18, SA-positive SLE) or the absence (n = 66, SA-negative
SLE) of nasal colonization. Renal involvement was significantly more frequent in SA-positive SLE (11.6 % vs 3.0 %;
P = 0.0009). Moreover, the presence of anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, anti-RNP antibodies was significantly
higher in SA-positive SLE (P < 0.0001, P = 0.01, P = 0.008, P = 0.03, P = 0.03, respectively).
Conclusion: SA colonization is a relatively frequent condition in patients with SLE, with a frequency similar to HS.
The presence of SA seems associated with a peculiar SLE phenotype characterized by renal manifestations and
autoantibody positivity, confirming the role of the microbiome in disease phenotype.
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Background
As widely demonstrated, genetic and environmental
factors interplay in the development of autoimmune dis-
eases, such as systemic lupus erythematosus (SLE) [1].
Several environmental factors have been implicated in
the different pathological conditions, and great emphasis
has been placed on the role of infection [2].
In recent years there has been growing interest in the
possible role of the microbiome in the development and
course of disease. Of note, the gut microbiome has been
widely investigated in autoimmune diseases, such as type
1 diabetes, inflammatory bowel diseases, rheumatoid arth-
ritis (RA), and spondyloarthropathies [3]. Conversely, few
data are available on the skin microbiome and the rela-
tionship with autoimmune diseases. Staphylococcus aureus
(SA) is a commensal microorganism and represents one
of the most important components of the human skin
microbiome [4]. SA is characterized by very heteroge-
neous pathogenic features, ranging from minor and self-
limiting skin infections, such as impetigo, folliculitis, and
furuncles, to invasive and life-threatening diseases, such as
septic arthritis, osteomyelitis, meningitis, septicemia and
staphylococcal toxic shock syndrome [5].
The anterior naris is the most frequent carriage site
for SA, due to specific anatomical and biochemical char-
acteristics facilitating the persistence of SA [6]. Data
from the National Health and Nutrition Examination
Survey 2001–2002 described a frequency up to 30 % of
SA colonization in the general population in the USA
[7]. A large cohort constituted by nine European coun-
tries described a frequency of SA carriage of 21.6 %, with
lower values in the older population [5]. In the great ma-
jority of the cases, this colonization is intermittent and
only in 20 % of cases is persistent [6].
Very few studies have evaluated the prevalence of SA
nasal carriage in patients affected by autoimmune dis-
eases and its association with the specific disease pheno-
type. In 1996 Tabarya and colleagues described a
prevalence of SA carriers of 50 % among patients with
RA from a cohort of 88 individuals, compared with 33 %
identified in a healthy control population [8]. More re-
cently, in 2005 Bassetti et al. did not identify any signifi-
cant difference in SA carrier prevalence, between RA
and a group of patients without, enrolled as controls
(34.5 % versus 32.5 %). Moreover, concomitant treat-
ment with tumor necrosis factor (TNF) antagonists and
methotrexate appeared to be the only independent factor
associated with carriage of nasal SA (OR 3.24) [9]. Con-
versely, a relationship between SA and granulomatosis
with polyangiitis (GPA) has been identified, suggesting
the role of this specific bacterium in disease develop-
ment and relapse [10]. Moreover, the study conducted
by Laudien and colleagues demonstrated a significantly
higher rate of SA nasal carriage in patients with GPA
compared to a cohort of patients with RA and staff
members (72.0 %, 46 %, and 58 %, respectively). Notably,
the risk of relapse was higher in patients with GPA who
had evidence of nasal SA [11].
Starting from the lack of studies in patients with SLE,
in the present analysis we aimed at assessing the preva-
lence of SA nasal carriers in a monocentric SLE cohort
and evaluated the association between SA nasal
colonization and disease phenotype.
Methods
Over a 3-month period, we enrolled 84 consecutive pa-
tients with SLE who had been referred to the Lupus
Clinic of the Rheumatology Unit, Sapienza University of
Rome (Sapienza Lupus Cohort). The diagnosis was per-
formed according to the revised 1997 American College
of Rheumatology (ACR) criteria [12]. One hundred fifty-
four healthy blood donors were enrolled as the control
group. Both patients and control subjects provided writ-
ten informed consent at the time of the visit.
At each visit, patients with SLE underwent a complete
physical examination. The clinical and laboratory data
were collected in a standardized, computerized, and
electronically filled form, including demographics, past
medical history with the date of diagnosis, comorbidities,
and previous and concomitant treatments. Disease mani-
festation was recorded according to the ACR classifica-
tion criteria [12].
Laboratory evaluation
The study protocol included the determination of autoanti-
bodies and the evaluation of C3 and C4 serum levels. Anti-
nuclear antibodies (ANA) were determined by means of
indirect immunofluorescence (IIF) on HEp-2 (titer ≥1:160
or ++ on a scale from + to ++++), anti-double-stranded
DNA (dsDNA) with IIF on Crithidia luciliae (titer ≥1:10),
ENA (including anti-Ro/SSA, anti-La/SSB, anti-Sm, and
anti-RNP) analyzed by enzyme-linked immunosorbent
assay (ELISA) considering titers above the cutoff of the ref-
erence laboratory, anti-cardiolipin (anti-CL) (IgG/IgM iso-
type) analyzed by ELISA, in serum or plasma, at medium
or high titers (e.g., >40 GPL or MPL or above the 99th per-
centile), anti-β2 Glycoprotein-I (anti-β2GPI) (IgG/IgM iso-
type) analyzed by ELISA, in serum (above the 99th
percentile), and lupus anticoagulant (LA), according to the
guidelines of the International Society on Thrombosis and
Hemostasis (scientific subcommittee on lupus anticoagu-
lant/phospholipid-dependent antibodies) [13]. Finally, C3
and C4 serum levels were determined by means of radial
immunodiffusion.
Disease activity and chronic damage
Disease activity was assessed by using the SLE Disease
Activity Index 2000 (SLEDAI-2 k) and the European
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Consensus Lupus Activity Measurement (ECLAM)
[14, 15]. For all patients with SLE, the occurrence of flare
and the presence of a persistently active disease in the
12 months prior to and the 12 months following the visit
were registered. Specifically, a flare was defined as an in-
crease in SLEDAI-2 K score ≥4 from the previous visit,
with a minimum interval of 2 months between visits and
persistently active disease as an SLEDAI-2 K score ≥4, ex-
cluding serology alone, on two or more consecutive visits
[16]. Finally, the SLICC Damage Index (SDI) was applied
to assess chronic damage [17].
Nasal swabbing
Both anterior nares were swabbed following a standard
operational procedure. BBL™ Culture Swab™ Collection
and Transport System (Made by Copan for Becton,
Dickinson, and Company, Sparks, USA) was used. Spe-
cifically, only one swab was used for both nares. The
swab should be inserted in the nasal vestibule, introdu-
cing only the cotton part of the swab. The operator
should rotate the swab while circulating in the nasal ves-
tibule for approximately 5 seconds. This procedure had
to be repeated in both nares [18]. Nasal swabbing was
performed at baseline and after specific treatment in
subjects positive for SA.
Microbiological evaluation
The total bacteria and colony forming units (CFU) of
each single bacterial strain, were analyzed for every sin-
gle swab. Bacteria were quantified by the standard plate
count method, in which the bacteria are grown in a nu-
trient culture and developing colonies counted. This
method entails diluting a sample with a specific buffer
diluent until the bacteria are sufficiently diluted to count
accurately, with the formation of colonies. In particular,
the CFU was used to estimate the number of viable bac-
teria in the sample. Specifically, swabs were cultured on
Columbia agar supplemented with 5 % sheep blood agar
at 37 °C under the ambient atmosphere for 48 h. CFUs
were then counted by macroscopic inspection. SA was
distinguished from Staphylococcus epidermidis by
hemolysis (b-hemolysis versus no hemolysis) and colony
color (golden yellow versus white), if necessary by agglu-
tination assay (Slidex Staph Plus, bioMérieux). Carrier
state was defined as a condition characterized by identi-
fication of SA on the nasal swab analysis in individuals
with no symptoms of skin or respiratory infection.
Treatment of SA nasal carriage
According to the protocol, all SA-positive patients were
treated by application of Mupirocin 2 % twice per day to
the nares for 5 days; this treatment was repeated
monthly for 12 months [19].
Epidemiologic background information
Both patients with SLE and healthy controls were invited
to fill a questionnaire in order to identify the presence of
factors increasing the risk of becoming an SA carrier. In
particular, the following information was registered:
1) Interaction with pets other than fish, specifying the
type
2) Contact with other animals, specifying the number
of times a week,
3) Hospitalization within 90 days (in the case of a
positive answer, the patient/subject had to specify
the reason and therapy)
4) Antibiotic treatment within 90 days (in the case of a
positive answer, the patient/subject had to specify
the reason and therapy)
5) Living with health care, veterinary, prison operators
6) Team sports practice
7) Previous SA infection requiring antibiotic treatment
Statistical evaluation
We used version 13.0 of the SPSS statistical package.
Normally distributed variables were summarized using
the mean ± standard deviation (SD) and non-normally
distributed variables by the median and range. Percent-
ages were used when appropriate. The Mann-Whitney
test was performed accordingly. Univariate comparisons
between nominal variables were calculated using the
chi-squared test or Fisher’s test where appropriate.
Multivariate analysis was performed using binary logistic
regression. In order to perform the multivariate analysis,
we used a step-forward model including, progressively,
those variables with P < 0.1 (as were those with a trend
towards significant association) to produce a stronger
model. Two-tailed P values were reported. P values
<0.05 were considered significant. Based on the number
of patients enrolled, and lacking data on the prevalence
of SA nasal carriage in patients with SLE, we planned a
study with 1.8 controls per case. The sample size was es-
timated by evaluating prior data in which the prevalence
of SA carriers among patients affected with RA ranged
between 34.6 and 46 % [8, 9], while in the larger cohort
reported previously, the prevalence of SA carriers among
the general population was 21.6 % [5]. Thus, if the true
probability of exposure among cases was 40 %, we
needed to study at least 74 case patients and 133 con-
trols to be able to reject the null hypothesis that the ex-
posure rates for cases and controls were equal with
probability (power) 0.8, with a type I error probability
(alpha) of 0.05.
Results
We enrolled 84 Caucasian patients with SLE and 154
healthy controls (HC). In Table 1 demographic, clinical,
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laboratory and treatment data for patients with SLE en-
rolled in the present study are described: all data refer to
the disease history. Healthy controls were 109 men and
45 women; mean age ± SD was 40.9 ± 9.7 years. There
were 20 patients with SLE who had concomitant auto-
immune diseases: 13 patients (65.0 %) with antiphospho-
lipid syndrome and 7 (35.0 %) with Sjögren’s syndrome.
No significant difference was found in mean age be-
tween patients with SLE and HC; conversely, male gen-
der was significantly more frequent in HC (41.3 %)
compared with patients with SLE (7.7 %; P < 0.001).
Comparison between SLE cases and healthy controls
Eighteen patients with SLE were nasal SA carriers
(21.4 %). This percentage was similar to that reported in
HC, in which 44 subjects were SA-positive (28.6 %; P =
0.3). Relevantly, in all cases, the identified SA strains
were methicillin-sensitive. No significant differences in
gender or age were identified in SLE or HC SA carriers
(Table 2). Moreover, in patients with SLE no association
between disease duration and SA colonization was ob-
served (Table 2). The evaluation of other factors associ-
ated with nasal colonization demonstrated a higher
frequency of antibiotic treatment within 90 days from
the assessment in SA-positive subjects (SLE 16.7 %, HC
10 %) compared with SA-negative subjects (SLE 12.2 %,
HC 3.2 %; P not significant (NS)). The frequency of the
risk factors associated with SA carriage is described in
Table 3 for both SLE and HC.
Comparison between SA-positive (SA+) and SA-negative
(SA-) patients with SLE
We then compared the clinical and laboratory features
of SA+ and SA- patients with SLE. The frequencies of
clinical manifestations in the two SLE groups at the time
of the study entry are reported in Fig. 1. Renal involve-
ment at the time of enrollment was significantly more
frequent was in SA+ patients with SLE, compared with
SA- patients (11.6 % vs 3.0 %; P = 0.0009). Similarly, al-
though not statistically significant, a higher frequency of
skin manifestations was observed in SA+ patients
(22.1 %) compared with SA- patients (15.1 %; P =NS).
Conversely, joint involvement was more frequent in SA-
patients (21.2 % vs 11.1 %; P = 0.02). The evaluation of
the autoantibody status in SA+ and SA- patients with
SLE demonstrated a similar frequency of ANA (100 %
versus 89.4 %; P =NS) at the time of the nasal swab.
Table 1 Demographic, clinical, laboratory features and used
treatments of patients with systemic lupus erythematosus (n = 84)
Demographic features Value
Male/female, n 6/78
Mean age ± SD (years) 41.3 ± 12.2
Mean disease duration ± SD (months) 142.1 ± 103.8
Clinical manifestations, n (%)
Joint involvement 57 (67.8)
Skin involvement 58 (69.0)
Serositis 18 (21.4)
Hematological manifestations 37 (44.0)
Neuropsychiatric involvement 10 (11.9)
Renal involvement 31 (36.9)
Laboratory manifestations, n (%)
Antinuclear antibodies 84 (100.0)
Anti-DNA 69 (82.1)
Anti-Sm 13 (15.5)
Anti-SSA 24 (28.6)
Anti-SSB 10 (11.9)
Anti-RNP 10 (11.9)
Anti-cardiolipin IgG/IgM 30 (35.7)
Anti-β2Glicoprotein I IgG/IgM 8 (9.5)
Lupus anticoagulant 12 (14.3)
Low C3 levels 32 (38.1)
Low C4 levels 44 (52.4)
Treatments, n (%)
Corticosteroids 60 (71.4)
Hydroxychloroquine 54 (64.3)
Cyclosporine A 19 (22.6)
Methotrexate 17 (20.2)
Cyclophosphamide 19 (22.6)
Mycophenolate mofetil 15 (17.8)
Azathioprine 18 (21.4)
ASA 25 (29.7)
Anticoagulant therapy 9 (10.7)
Table 2 Epidemiological features in patients with systemic
lupus erythematosus (SLE) and healthy control (HC) subjects
according to nasal carriage status
SLE
(n = 84)
HC
(n = 154)
P
Nasal SA carrier prevalence (%) 21.4 28.6 NS
Male/female, n
SA-positive 1/17 32/12
SA-negative 5/61 77/33 NS
Mean age ± SD (years)
SA-positive 40.9 ± 11.8 38.7 ± 12.6 NS
SA-negative 41.3 ± 12.4 41.6 ± 8.9
Mean disease duration ± SD (months)
SA-positive 150.0 ± 107.1 - NS
SA-negative 139.6 ± 103.6 -
SA Staphyloccocus aureus, NS not significant
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Interestingly, a significantly higher prevalence of anti-
dsDNA, anti-Sm, anti-SSA, anti-SSB, and anti-RNP anti-
bodies was identified in SA+ patients with SLE (77.7 %,
22.2 %, 44.4 %, 16.6 %, and 16.6 %, respectively) com-
pared with SA- patients (39.4 %, P < 0.0001; 9.1 %, P =
0.01; 21.1 %, P = 0.0008; 6.1 %, P = 0.03; and 6.1 %, P =
0.03, respectively; Fig. 2). The results differed for anti-
phospholipid antibodies: aCL positivity was observed
only in SA- patients with SLE. Moreover, there were no
significant differences between SA+ and SA- patients
with SLE in the prevalence of LA and anti-β2GPI.
C3 and C4 levels were more frequently reduced in SA-
patients with SLE (low C3 levels: 19 patients (29.7 %)
SA- vs 3 patients SA+ (16.6 %); P = 0.01; low C4 levels:
21 patients (32.8 %) SA- vs 4 patients SA+ (22.2 %; P =
0.03). The evaluation of SLE treatment in the two groups
of patients revealed significantly more glucocorticoid
treatment in the SA+ SLE group (15 patients (83.3 %))
compared with the SA- group (43 patients (65.1 %); P =
0.01). There were no significant differences in the mean
weekly prednisone (or equivalent) dosage (SA+ patients
40.2 ± 21.3 mg/week vs 49.1 ± 41.1 mg/week; P =NS).
The multivariate analysis confirmed the association
between SA carriage status and positivity for anti-
dsDNA (P = 0.003).
We also evaluated disease activity and chronic damage
at the time of study enrollment. We did not find signifi-
cant differences between SA+ and SA- patients with SLE
in SLEDAI-2 k values (3.1 ± 3.6 vs 2.5 ± 2.4; P =NS),
ECLAM (1.0 ± 0.1 vs 1.0 ± 0.9, P =NS) and SDI (0.1 ± 0.3
vs 0.3 ± 0.7, P =NS). In order to evaluate the role of SA
nasal colonization in disease activity modification, we
evaluated the frequency of persistently active disease and
flares in the 12 months preceding study entry. We iden-
tified a trend towards higher frequency of persistently
active disease in SA+ patients with SLE (27.7 %) com-
pared with SA- patients (17.2 %; P =NS). A similar
prevalence of flares was identified in the two groups in
the previous 12 months (SA+ patients 11.1 %, SA- pa-
tients 9.3 %; P =NS).
Treatment and follow up of SA+ patients with SLE
All the SA+ patients with SLE were treated with Mupir-
ocin 2 % twice per day to the nares for 5 days. A nasal
swab was repeated 2 weeks after the first treatment,
demonstrating the absence of SA colonization in all the
cases re-evaluated. Moreover, no differences were found
before and after treatment in the frequency of flares
(two flares (11.1 %) in the two groups over the 12-
month follow up) and persistently active disease (before
eradication: 5 patients (27.7 %); after eradication: 4 pa-
tients (22.2 %)).
Discussion
In the present study, for the first time we evaluated the
prevalence of SA nasal colonization in a cohort of pa-
tients affected by SLE. Despite a similar frequency of SA
being observed in patients and a healthy control group,
the SA colonization in patients with SLE was associated
with a specific disease phenotype, characterized by renal
and skin involvement, and a higher prevalence of a
broad spectrum of autoantibodies.
SLE is an autoimmune disease characterized by very
heterogeneous autoantibody production and clinical
manifestations [1]. Infectious agents seem to play an im-
portant role in disease pathogenesis due to their ability
to activate B-cell-mediated and T-cell-mediated auto-
immune responses leading to the production of auto-
antibodies [2, 20]. More recently, the interferon (IFN)
signature was shown as an additional mechanism in-
volved in the disease, confirming the possible role of in-
fection [21]. Moreover, innate immunity through
pathogen-associated molecular patterns and Toll-like re-
ceptors (TLRs) may also contribute to disease develop-
ment [22].
The microbiome is a novel and intriguing concept that
has been reported to be involved in the pathogenesis of
Table 3 Epidemiologic background information in patients with
systemic lupus erythematosus (SLE) and healthy controls (HC)
SLE HC P
Interaction with pets (%)
SA-positive 16.7 20.0 NS
SA-negative 24.4 22.6
Contacts with other animals (%)
SA-positive 22.2 0 P < 0.0001 SLE SA-positive
vs HC SA-positive
SA-negative 12.2 12.9 P = 0.0001 HC SA-negative
vs HC SA-positive
Hospitalization within 90 days (%)
SA-positive 0 0 NS
SA-negative 1.5 0
Antibiotic treatment within
90 days (%)
SA-positive 16.7 10.0
SA-negative 12.2 3.2 P = 0.02 SLE SA-negative
vs HC SA-negative
Team sports practice (%)
SA-positive 5.5 30.0 P < 0.001 SLE SA-positive
vs HC SA-positive
SA-negative 0 3.2 P < 0.001 HC SA-positive
vs HC SA-negative
Previous SA infections (%)
SA-positive 0 0 NS
SA-negative 3.0 0
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several autoimmune diseases. Most studies focused on
the gut microbiome; nonetheless, the skin microbiome
could play a role in human autoimmune conditions.
Changes in the skin microbiome seem to influence the
disease course through the modulation of the cutaneous
immune system. Moreover, each individual has a unique
skin microbiome influenced by pH, salinity, sebum con-
tent of the topographical body region, and by intrinsic
(e.g. genotype, age, and sex) and extrinsic individual-
dependent factors (e.g., occupation, geographical location,
smoking, sun exposure, and use of antibiotics or cos-
metics) [4]. SA is one of the components of the skin
Fig. 1 Clinical features in Staphyoloccocus aureus-positive (SA+) and SA-negative (SA-) patients with systemic lupus erythematosus at the time of
enrollment. NPSLE: Neuropsychiatric SLE
Fig. 2 Laboratory features in Staphyoloccocus aureus-positive (SA+) and SA-negative (SA-) patients at the time of enrollment. LA: Lupus
Anticoagulant; aB2GPI: anti-β Glycoprotein I, aCL: anti-cardiolipin
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microbiome that could potentially colonize all body sur-
faces including the gut and anterior nares [5, 6].
It seems to induce an inflammatory response by ex-
posing staphylococcal superantigen, molecular mimicry,
causing increased TLR signaling in leukocytes and indu-
cing neutrophil extracellular traps [6, 10]. Moreover, SA
seems to be able to interact with endothelial, B and T
cells, leading to the activation of neutrophils and the
production of pro-inflammatory cytokines [23]. Age, sex,
and ethnicity influence SA colonization. Indeed, signifi-
cantly higher colonization rates are identified in younger
people, in men, and in white populations [6]. Several
pathological conditions, such as diabetes mellitus, hemo-
dialytic treatment, end-stage liver disease, obesity, and
HIV infection, predispose to nasal SA [6].
To our knowledge, no data on SA colonization in pa-
tients with SLE are available so far. Only two studies
have been performed in patients with RA. In both ana-
lyses, a higher prevalence of SA carriers was found com-
pared to our SLE cohort, and also the prevalence in
their control groups was higher than that observed in
our HC [9, 11]. Thus, we could reasonably exclude that
disease per se or differences in the immunosuppressive
treatment could justify such an observation. It is more
likely that the conditions in which the swab was ob-
tained or differences between the studied populations in
age, sex, and ethnicity, could justify such a result.
Intriguingly, we observed that the presence of SA was
associated with a specific phenotype of SLE, namely
characterized by high frequency of different autoanti-
bodies (anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, and
anti-RNP) and by a more frequent renal and skin in-
volvement. Indeed, SA carriers had a significantly higher
prevalence of anti-SSA and anti-SSB antibodies, which
are known to be associated with cutaneous involvement.
In addition, anti-dsDNA and anti-Sm antibodies, which
are associated with renal involvement, were present in
SA+ patients [24].
It could be hypothesized that SA carriage status in-
duces the production of autoantibodies. No data are
available on this topic in patients with SLE. It is possible
that SA, by stimulating the type-I IFN pathway, leads to
increased production of autoantibodies and therefore to
the development of the previously mentioned clinical
manifestations [25]. Indeed, dendritic cells (DC), able to
recognize pathogens, to activate T cells and to product
the type I IFNs, could take up SA through an endocytic
mechanism, resulting in the activation of TLR9 signal-
ing. As known, TLR9 is localized at the endosomal level
and is involved in autoimmune responses to DNA-
associated proteins [22, 26]. Moreover, SA is able, inde-
pendently of TLR2, to activate human plasmacytoid DC
and subsequent IFN-α secretion [27, 28]. The study pub-
lished by Viau in 2005, evaluating the effects of repeated
injection of SA protein A on the (NZBxNZW) F (1)
mice lupus model, demonstrated the reduction of
anti-DNA IgG production and of proteinuria. The authors
suggested that this result could be related to the depres-
sion of B-cell response induced by the protein A [29]. As
widely demonstrated, SA could interact with both the in-
nate and adaptive immune responses by different virulence
factors, among these, the SA protein A, characterized by
the presence of immunoglobulin-binding domains, able to
bind the Fab of VH3 idiotype antibodies [30, 31].
It should be considered that SA could influence im-
mune response also by the activation of T cells. Data
from the literature demonstrated that Staphylococcal en-
terotoxins (SEs) could bind directly the major histocom-
patibility complex (MHC) class II of antigen-presenting
cells. The presentation to T cells leads to massive non-
specific activation of the immune system, by stimulating
around 20 % of the naïve T-cell population [32].
The higher prevalence of SA nasal colonization was not
associated with any treatment except glucocorticoids. Data
from the literature demonstrate that cortisol status can in-
fluence susceptibility to infection and that glucocorticoids
seem able to reduce the release of pro-inflammatory cyto-
kines, the activation of anti-inflammatory genes, the upreg-
ulation of cell adhesion molecules and the downregulation
of neutrophil adhesion molecules, thus facilitating the onset
of an infective process [33]. Furthermore, Van den Akker
and colleagues suggested an association between SA carrier
status and polymorphisms of the glucocorticoid receptor
gene. Those subjects homozygous for the haplotype 3,
which is associated with relative glucocorticoid resistance,
had 68 % decreased risk of persistent nasal carriage. Con-
versely, the genotype combination of the haplotype 5 and
the haplotype 1 allele was associated with 80 % increased
risk of persistent nasal carriage [34]. It would also be of
interest to assess the genotype of the glucocorticoid recep-
tor gene in a population of patients with SLE.
Moreover, it should be considered that glucocorticoid
treatment could determine skin abnormalities. In particu-
lar, permeability barrier homeostasis and stratum corneum
integrity and cohesion could be modified by glucocortic-
oid treatment, also when performed for a brief period.
This could be related to inhibition of the synthesis of epi-
dermal lipid exerted by glucocorticoids [35].
We could not find any significant difference in disease ac-
tivity nor in the number of flares between SA+ and SA- pa-
tients with SLE and only a trend towards higher frequency
of persistently active disease was identified in SA+ patients.
This result could be related to the single SA assessment
performed in the study. SA colonization can vary during
the time and it would be of interest to link SA colonization
with the occurrence of disease flares. On the other hand,
the identification of persistent carriers should be evaluated
in relation to the development of more severe chronic
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damage. In this view, we evaluated disease activity modifi-
cations after treatment. The lack of a significant improve-
ment in the disease course evaluated 12 months after the
successful eradication with muropicin could be due to the
follow up being too short, or to the weak influence of nasal
SA on disease activity. Finally, we evaluated only the anter-
ior nares, despite possible colonization in different body
sites. However, the primary reservoir for SA in humans is
the anterior nares, probably due to the high affinity for
nasal epithelial cells. Moreover, nasal secretions also seem
to improve the bacterium adherence, in particular, thanks
to clumping factor B and iron-regulated surface determin-
ant A. Therefore, in this study we decided to evaluate the
colonization of SA exclusively in the anterior nares [36].
A limitation of the present study is the SA identification
by a classical morphological evaluation, without molecular
characterization. Moreover, the cross-sectional design and
the evaluation of nasal SA at a single time point did not
allow the exclusion of transient carriers.
Conclusions
In conclusion, although the small size of the SLE cohort
evaluated does not allow definitive conclusions, SA
colonization is a relatively frequent event in the course
of SLE. The presence of SA seems associated with a pe-
culiar SLE phenotype characterized by cutaneous and
renal manifestations. It is not possible to determine
whether this is an epiphenomenon rather than a causal
factor. Certainly, the skin microbiome deserves deeper
investigation, as it may influence disease onset and
features.
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